{"Clinical Trial ID": "NCT00580333", "Intervention": ["INTERVENTION 1:", "- Cisplatin/Avastine", "Cisplatin 75mg/m2 every 3 weeks, neoadjuvant bevacizumab 15mg/m2 every 3 weeks, neoadjuvant doxorubicin, adjuvant (optional) cyclophosphamide, adjuvant (optional) paclitaxel, adjuvant (optional)", "Cisplatin: Preoperative: administered intravenously on the first day of the treatment cycle (once every 3 weeks) for four cycles", "Bevacizumab: Preoperatively: administered intravenously on day 1 of the treatment cycle (once every three weeks) for three cycles Postoperatively: intravenously for four cycles of 2 weeks (once every two weeks) and after 8 weeks (the doctor's study will determine the course of treatment) for four additional cycles of 2 weeks with or with paclitaxel", "Doxorubicin: Postoperative: administered intravenously for four 2-week cycles", "Cyclophosphamide: Postoperative: administered intravenously for four two-week cycles", "Paclitaxel: Postoperative: 8 weeks after postoperative chemotherapy (the study doctor will determine the course of treatment) paclitaxel for four cycles of 2 weeks (once every two weeks)"], "Eligibility": ["Incorporation criteria:", "All tumours should be ER-, PR-, and HER2-negative", "Clinical level T2 or T3, N0-3, M0. Subjects with inflammatory breast cancer are not eligible.", "For subjects with clinically negative axilla, sentinel lymph nodes biopsy will be performed either before or after preoperative treatment at the discretion of the subject's physicians; for subjects with clinically positive axilla, needle aspiration or nucleus biopsy will be performed to confirm the presence of metastatic disease in lymph nodes.", "- 18 years or older", "State of execution (PS) of 0 or 1", "Use of effective contraception in people of childbearing age", "Normal organ function as described in the protocol", "- Exclusion criteria:", "Any prior chemotherapy or cytotoxic radiation for current breast cancer", "HER2-negative recurrence of ipsilateral breast, unless the previous treatment consisted of excision alone for in situ channel carcinoma (CDIS) or breast preservation treatment and hormonal treatment for DCIS or invasive cancer", "\u2022 Life expectancy less than 12 weeks", "Current, recent or planned participation in an experimental study of bevacizumab cancer other than a study sponsored by Genentech", "\u2022 Renal dysfunction for which exposure to cisplatin would require dose changes", "Asthma dependent on steroids", "- Peripheral neuropathy of any etiology greater than Class 1", "- Uncontrolled diabetes", "\u2022 History of malignity treated without curative intent", "Any other pre-existing medical condition that is more toxic than Class 1", "Poorly controlled blood pressure", "Any history of hypertensive seizure or hypertensive encephalopathy", "New York Heart Association (NYHA) Grade II or more congestive hearing failure", "History of myocardial infarction or unstable angina within 12 months of enrolment", "Any history of stroke or transient ischemic attack at any time", "Known central nervous system disease (CNS)", "Important vascular disease", "A symptomatic peripheral vascular disease", "Evidence of haemorrhagic diathesis or coagulopathy", "\u2022 Major surgery, open biopsy, or significant traumatic injury within 21 days of being enrolled in the study", "\u2022 History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscesses within 6 months prior to study enrollment", "Serious non-healing injury, ulcer or bone fracture", "\u2022 Screening proteinuria", "\u2022 Known hypersensitivity to any component of bevacizumab", "\u2014 Pregnant or lactating"], "Results": ["Performance measures:", "\u00b7 Complete pathological response rate following preoperative treatment with Cisplatin and Bevacizumab in human epidermal growth factor ER receptor 2, PR (HER2) - Negative early breast cancer.", "The objective of this measure was to determine the complete pathological response rate ( Miller-Payne score (MP) 5) after preoperative treatment with cisplatin and bevacizumab in early negative breast cancer of ER, RA and HER2.", "Time limit: 2 years", "Results 1:", "Title of arm/group: Cisplatin/Avastin", "Description of the arm/group: Cisplatin 75mg/m2 every 3 weeks, neoadjuvant bevacizumab 15mg/m2 every 3 weeks, neoadjuvant doxorubicin, adjuvant (optional) cyclophosphamide, adjuvant (optional) paclitaxel, adjuvant (optional)", "Cisplatin: Preoperative: administered intravenously on the first day of the treatment cycle (once every 3 weeks) for four cycles", "Bevacizumab: Preoperatively: administered intravenously on day 1 of the treatment cycle (once every three weeks) for three cycles Postoperatively: intravenously for four cycles of 2 weeks (once every two weeks) and after 8 weeks (the doctor's study will determine the course of treatment) for four additional cycles of 2 weeks with or with paclitaxel", "Doxorubicin: Postoperative: administered intravenously for four 2-week cycles", "Cyclophosphamide: Postoperative: administered intravenously for four two-week cycles", "Paclitaxel: Postoperative: 8 weeks after postoperative chemotherapy (the study doctor will determine the course of treatment) paclitaxel for four cycles of 2 weeks (once every two weeks)", "Total number of participants analysed: 51", "Type of measurement: Number", "Unit of measure: percentage of participants 16 (7-29)"], "Adverse Events": ["Undesirable Events 1:", "Total: 0/51 (0.00 per cent)"]}